Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA

　　Drug Overview and Development Background

　　Simtriyo(generic name:centanafadine)is a proprietary product developed by Otsuka Pharmaceutical,Japan.Commercial distribution in the United States is managed by its wholly owned subsidiary,OPDC.The drug is formulated as a once-daily extended-release oral capsule and represents a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor(NDSRI),exerting its therapeutic effect by simultaneously blocking the reuptake of three monoamine neurotransmitters.

　　Unlike existing ADHD medications that target only one or two neurotransmitter systems,centanafadine achieves triple-pathway modulation.This mechanism addresses both the core symptoms of inattention and hyperactivity-impulsivity while concurrently supporting emotional regulation.Its non-stimulant pharmacological profile confers a substantially lower risk of abuse and dependence compared to conventional central nervous system stimulants.

　　Regulatory Pathway and Launch Timeline

　　The FDA evaluated the new drug application through its Priority Review pathway and issued a formal approval decision on July 24,2026.Following completion of the Drug Enforcement Administration(DEA)scheduling process,Simtriyo is anticipated to be broadly available in U.S.retail pharmacies by the end of 2026.

　　Indication and Target Population

　　The approved indication encompasses pediatric patients aged 6 years and older with a body weight of at least 20 kg,adolescents,and adults diagnosed with ADHD,with no upper age limit.This broad labeling spans school-age children,middle and high school students,college students,and working adults.The drug is particularly suited for the following clinical scenarios:ADHD patients with comorbid generalized anxiety disorder or social anxiety disorder;patients who are intolerant of or have contraindications to traditional CNS stimulants such as methylphenidate or amphetamine-based products;and patients requiring a long-term management strategy with minimal abuse liability.

　　Disease Background and Unmet Medical Need

　　Attention-deficit/hyperactivity disorder is a chronic neurodevelopmental condition characterized by persistent inattention,hyperactivity,and impulsivity,with symptoms often persisting from childhood into adulthood.Over 22.5 million individuals carry a confirmed ADHD diagnosis in the United States,and nearly half of adult patients concurrently suffer from anxiety disorders.Current treatment faces two major challenges:stimulant medications,while efficacious,carry inherent risks of misuse and dependence;non-stimulant agents often address only a single symptom dimension and lack meaningful efficacy against comorbid emotional disturbances.The approval of Simtriyo addresses this critical therapeutic gap.

　　Pivotal Phase III Clinical Trial Evidence

　　The FDA approval was supported by four global,multicenter,randomized,double-blind,placebo-controlled Phase III registration trials spanning adult,adolescent,and pediatric populations.Total enrollment exceeded 1,800 subjects,with a six-week treatment observation period and primary efficacy endpoints assessed via validated ADHD rating scales.

　　In the adult cohort(n=906),both the high-dose and low-dose groups demonstrated statistically significant improvements over placebo on the Adult ADHD Investigator Symptom Rating Scale(AISRS)total score,with observable symptom relief in attention and impulsivity domains as early as Week 1.Subgroup analyses confirmed additional emotional benefits in adults with comorbid anxiety.

　　In the adolescent cohort(ages 13–17),the high-dose group achieved a placebo-adjusted improvement of 4.35 points on the ADHD Rating Scale,5th edition(ADHD-RS-5)total score(P=0.0006);the low-dose group did not meet the primary endpoint.

　　In the pediatric cohort(ages 6–12),the high-dose group demonstrated statistically significant symptom improvement(P=0.0008),while the low-dose group failed to reach the predefined threshold.

　　Additionally,Otsuka disclosed results from a Phase 3b supplemental study in June 2026,enrolling 315 adults with ADHD and comorbid anxiety(GAD or SAD).This trial met both its primary and key secondary endpoints,further validating centanafadine's efficacy advantage in the comorbid population.

　　Overall safety data indicated that adverse events were predominantly mild to moderate in severity,including decreased appetite,insomnia,nausea,dry mouth,and rash.No signals of serious organ toxicity were identified.Long-term follow-up confirmed sustained efficacy.

　　Safety Warnings and Precautions

　　The prescribing information highlights the following key safety considerations:common adverse reactions include decreased appetite,difficulty falling asleep,nausea,dry mouth,and rash;clinicians should monitor for manic or hypomanic episodes,particularly in patients with a history of bipolar disorder;cardiovascular parameters including heart rate and blood pressure require periodic monitoring;concomitant use with monoamine oxidase inhibitors(MAOIs)is strictly contraindicated,with an adequate washout interval mandated between the two agents;pediatric and adolescent patients require regular assessment of growth parameters(height,weight)and behavioral-emotional status throughout treatment.

　　Dosing Regimen

　　Simtriyo is administered as a single once-daily extended-release capsule.The appropriate fixed-dose strength is selected based on patient age,body weight,and symptom severity.The capsule should be swallowed whole at a consistent time each day without the need for divided dosing,simplifying the medication routine and enhancing long-term adherence among school-age children and working professionals.Treatment duration and potential dose tapering are determined by the treating physician based on individual symptom control.

　　Clinical Value and Industry Significance

　　Simtriyo establishes a new paradigm of triple-neurotransmitter modulation in ADHD pharmacotherapy,achieving integrated coverage of attention enhancement,hyperactivity-impulsivity control,and comorbid anxiety management for the first time.The once-daily extended-release formulation aligns seamlessly with academic schedules and professional work routines.Its non-stimulant mechanism fundamentally reduces abuse potential.The all-age indication eliminates the previous fragmentation between pediatric and adult drug selection,setting a new benchmark for stratified,long-term ADHD management.

　　Corresponding Medical Department

　　Psychiatry/Child and Adolescent Psychiatry/Neurology

　　ADHD diagnosis and treatment may fall under different departments depending on the healthcare institution:general hospitals typically manage ADHD through psychiatry or psychology departments;pediatric specialty hospitals often have dedicated child psychiatry or developmental-behavioral pediatrics units;some institutions also assign adult ADHD care to neurology departments.